undefined

undefined

doi:undefined

https://doi.org/10.14740/jh2196

Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia.

Apr 1, 2026
Journal of hematology
Jennifer Cai +2 more

Listen

TL;DR

Harlequin cells, abnormal eosinophils with large basophilic granules, were identified in 72% of CML cases and are rare in other myeloproliferative neoplasms, suggesting that their recognition on blood smears can serve as a sensitive and specific morphological marker to aid in the prompt diagnosis of CML and guide confirmatory testing.

Abstract

Translate Article

Chronic myeloid leukemia (CML) often presents with hematologic findings that overlap with reactive leukocytosis and other myeloproliferative neoplasms (MPNs), creating diagnostic uncertainty that may delay targeted therapy or prompt unnecessary molecular testing. Harlequin cells-abnormal eosinophils containing basophilic granules-are well described in acute myeloid leukemia (AML) with CBFB::MYH11 fusion, but their diagnostic relevance in CML has not been systematically assessed. We retrospectively reviewed 177 peripheral blood smears: 53 CML; 30 non-CML MPN and related disorders; 59 AML (including three with CBFB::MYH11 fusion); 11 eosinophilia; and 24 reactive cytosis cases. Harlequin cells were stringently defined as abnormal eosinophils containing both typical eosinophilic granules and large, distinctly basophilic (not purplish-orange) cytoplasmic granules to exclude reactive mimics. Harlequin cells were identified in 72% (38 out of 53) of CML cases, a frequency significantly higher than in non-CML MPN (10%, P < 0.01), AML without CBFB::MYH11 fusion (3.6%, P < 0.01), eosinophilia (0%), and reactive cytosis (0%) groups. They were also observed in 67% (2/3) of AML with CBFB::MYH11 fusion and in 20% (3/15) of primary myelofibrosis, but were absent in polycythemia vera, essential thrombocythemia, and chronic myelomonocytic leukemia. Strictly defined Harlequin cells were not found in any reactive condition. In the appropriate clinical context, strictly defined Harlequin cells on routine peripheral blood smears may serve as a sensitive and highly specific morphologic clue for CML. Recognition of this readily accessible feature may facilitate prompt BCR::ABL1 confirmatory testing, reduce diagnostic ambiguity, and help avoid unnecessary ancillary studies.

Similar Papers

Abstract
3
10.1182/blood.v108.11.118.118

Hypermethylation of SH2-Containing Phosphatase-1 (SHP-1) and Suppressor of Cytokine Signaling-1 and -3 (SOCS-1 and -3) in Philadelphia Negative Chronic Myeloproliferative Disorders (Ph-CMPD).

Nov 16, 2006
Blood
Davide Rossi + 11 more

Hypermethylation of SH2-Containing Phosphatase-1 (SHP-1) and Suppressor of Cytokine Signaling-1 and -3 (SOCS-1 and -3) in Philadelphia Negative Chronic Myeloproliferative Disorders (Ph-CMPD).

Research Article
31
10.2353/jmoldx.2006.050064

Detection of the Single Hotspot Mutation in the JH2 Pseudokinase Domain of Janus Kinase 2 in Bone Marrow Trephine Biopsies Derived from Chronic Myeloproliferative Disorders

May 1, 2006
The Journal of Molecular Diagnostics
Oliver Bock + 5 more

Detection of the Single Hotspot Mutation in the JH2 Pseudokinase Domain of Janus Kinase 2 in Bone Marrow Trephine Biopsies Derived from Chronic Myeloproliferative Disorders

Research Article
7
10.1046/j.1365-2141.1999.14354210.x

Myelodysplasia and myeloproliferative disorders in childhood: an update

Jun 1, 1999
British Journal of Haematology
Peter D Emanuel

Myelodysplasia and myeloproliferative disorders in childhood: an update

Research Article
25
10.1046/j.1365-2141.2001.02994.x

Pitfalls in the diagnosis of childhood leukaemia.

Sep 1, 2001
British Journal of Haematology
Judith M Chessells

Pitfalls in the diagnosis of childhood leukaemia.

Research Article
38
10.1046/j.1365-2141.2002.03469.x

Receptor tyrosine kinase mutations in myeloid neoplasms.

May 19, 2002
British journal of haematology
Rajeev Gupta + 2 more

Receptor tyrosine kinase mutations in myeloid neoplasms.

Abstract
3
10.1182/blood-2024-208963

Associations between Myeloid Malignancies and Osteoporosis Using Real-World Data from the Trinetx Database

Nov 5, 2024
Blood
Shireen J Usman + 4 more

Associations between Myeloid Malignancies and Osteoporosis Using Real-World Data from the Trinetx Database

Research Article
48
10.4065/81.4.553

Atypical Myeloproliferative Disorders: Diagnosis and Management

Apr 1, 2006
Mayo Clinic Proceedings
Ayalew Tefferi + 2 more

Atypical Myeloproliferative Disorders: Diagnosis and Management

Research Article
95
10.1046/j.1365-2141.2002.03234.x

CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?

Jan 1, 2002
British Journal of Haematology
John T Reilly

CHRONIC NEUTROPHILIC LEUKAEMIA: A DISTINCT CLINICAL ENTITY?

Research Article
218
10.1046/j.1365-2141.2003.04195.x

The eosinophilias, including the idiopathic hypereosinophilic syndrome.

Apr 1, 2003
British Journal of Haematology
Finella Brito‐Babapulle

The eosinophilias, including the idiopathic hypereosinophilic syndrome.

Research Article
26
10.3324/haematol.2014.109199

Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.

Jul 11, 2014
Haematologica
C Qiao + 6 more

The Janus kinase 2 (JAK2) V617F mutation (JAK2 V617F), JAK2 exon 12 mutations and myeloproliferative leukemia virus oncogene W515L/K mutation (MPL W515L/K) have become three major molecular diagnosis criteria for myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) from 2005. 1 However, diagnosing MPNs with non-mutated JAK2 and MPL remains a major diagnostic challenge. 2-4 6] Here, we report our data on CALR mutation in wild-type (wt) JAK2 MPN on patients. It should also be mentioned that this is undoubtedly the first report regarding CALR mutations in Chinese MPN patients.